Overview

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Chinese PLA General Hospital
Collaborator:
Cure&Sure Biotech Co., LTD
Treatments:
Oxaliplatin
Vaccines